VTE Guideline Weighs in on Newer Oral Anticoagulants

A revised guideline from the American College of Chest Physicians favors the use of dabigatran, rivaroxaban, apixaban, or edoxaban over traditional vitamin K antagonist (VKA) or low-molecular-weight heparin (LMWH) therapy for the long-term treatment of venous thromboembolism (VTE) in patients without cancer.

Article Source: